Incyte Corp

INCY: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|#>LOCK|N#!LOCK|j?<C@Y

Incyte Earnings: Maintaining Our $88 Fair Value Estimate on Strong Jakafi Demand, Opzelura Expansion

Narrow-moat Incyte reported robust third-quarter results in line with our expectations. We are maintaining our $88 fair value estimate and continue to think that the market is underappreciating the firm's potential to grow past Jakafi's patent expiration in 2028. Despite the stock's 12% rally today, we view Incyte's shares as moderately undervalued.

Sponsor Center